More on PBM
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.95 |
|
|||
| Open | $3.92 | ||||
| 52 Wk High | $4.56 | ||||
| 52 Wk Low | $0.45 | ||||
| Day High | $4.00 | ||||
| Day Low | $3.39 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 155,925 | ||||
- Form SCHEDULE 13D PSYENCE BIOMEDICAL LTD. Filed by: Psyence Labs Ltd
- Psyence BioMed executives to visit US for ibogaine research meetings
- Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
- Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 23
- Psyence BioMed begins dosing patients in phase IIb psilocybin trial
- Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
- Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 17
- Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 20
- Psyence BioMed reports GMP-compliant ibogaine inventory for research
- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Entities mentioned with PBM
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- F1 | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- Show More...
